MedPath

CPK Levels After LC and Association With Analgesic Modalities

Completed
Conditions
Myotoxicity
Registration Number
NCT06508177
Lead Sponsor
Samsun University
Brief Summary

Regional anesthesia and analgesia technics are widely and securely used during general surgery procedures. Interfascial plane blocks are the latest used ones for analgesia. There are studies in literature indicating that bupivacaine cause myotoxicity. The investigators aimed to examine plasma creatine phosphokinase (CPK) levels to see whether myotoxicity occurs or not after fascial plane blocks are applied to patients undergoing laparoscopic cholecystectomy.

Detailed Description

During 3 months period all elligible patients undergoing laparoscopic cholecystectomy surgery will be included in the study. Different postoperative analgesic modalities will be used according to the anesthesists experience. During routine blood sample tests plasma creatin phosphokinase (CPK) levels will be tested 3 times of all patients(preoperative, postoperative 6th hour, postoperative 24th hour). Data will be analysed and patients will be grouped according to the analgesic modalities used.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
80
Inclusion Criteria
  • ASA 1-3
  • Laparoscopic cholecystectomy
  • under General Anesthesia
Exclusion Criteria
  • Morbidly obesity or cachexia
  • local anesthetic allergies
  • myopathies
  • coagulopathies
  • Obstructive sleep apne syndrome
  • hearth diseases
  • liver diseases
  • kidney diseases
  • thyroid-parathyriod dieseas
  • hiperlipidemias using Statins(HMG-CoA reductase inhibitors)
  • pregnancy

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
CPK levelsat postoperative 24th hour

Serum creatine phosphokinase levels at 24th hour

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Samsun University

🇹🇷

Samsun, Turkey

Samsun University
🇹🇷Samsun, Turkey

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.